These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7778056)

  • 1. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury.
    Terashita Z; Imura Y; Kawamura M; Kato K; Nishikawa K
    Thromb Res; 1995 Mar; 77(5):411-21. PubMed ID: 7778056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model.
    Imura Y; Kiyota Y; Nagai Y; Nishikawa K; Terashita Z
    Thromb Res; 1995 Jul; 79(1):95-107. PubMed ID: 7495108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings.
    Terashita Z; Imura Y; Nishikawa K
    J Lipid Mediat Cell Signal; 1996 Jan; 13(1):1-8. PubMed ID: 8821806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
    Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
    Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
    Terashita Z; Imura Y; Tanabe M; Kawazoe K; Nishikawa K; Kato K; Terao S
    Thromb Res; 1986 Jan; 41(2):223-37. PubMed ID: 3083523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of thromboxane (TX) A2 in rabbit arterial thrombosis induced by endothelial damage.
    Imura Y; Terashita Z; Nishikawa K
    Thromb Res; 1990 Jul; 59(1):195-205. PubMed ID: 2119075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
    Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs.
    Shirakura S; Higo K; Takeda M; Karasawa A
    Jpn J Pharmacol; 1994 Jun; 65(2):93-8. PubMed ID: 7967232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat.
    Herbert JM; Bernat A; Samama M; Maffrand JP
    Thromb Haemost; 1996 Jul; 76(1):94-8. PubMed ID: 8819259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate.
    Asai F; Ito T; Ushiyama S; Matsuda K; Oshima T
    Arzneimittelforschung; 1991 May; 41(5):506-10. PubMed ID: 1898421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase].
    Nakazawa M; Iizuka K; Ujiie A; Hiraku S; Ohki S
    Yakugaku Zasshi; 1994 Dec; 114(12):911-33. PubMed ID: 7869235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of antigen-induced airway hyperresponsiveness in rats: effects of ozagrel (a thromboxane A2 synthase inhibitor) and of CV-3988 (a platelet activating factor antagonist).
    Misawa M; Chiba Y
    Res Commun Chem Pathol Pharmacol; 1994 Jun; 84(3):341-9. PubMed ID: 7938906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets.
    Naito J; Komatsu H; Ujiie A; Hamano S; Kubota T; Tsuboshima M
    Eur J Pharmacol; 1983 Jul; 91(1):41-8. PubMed ID: 6413227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effects of anti-thromboxane agents in platelet-vessel wall interaction.
    Buccellati C; Ciceri P; Ballerio R; Casagrande C; Folco G; Nicosia S
    Eur J Pharmacol; 2002 May; 443(1-3):133-41. PubMed ID: 12044803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.